Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes.
Type 1 diabetes
immunotherapy
insulin
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
02
08
2021
accepted:
22
09
2021
pubmed:
24
9
2021
medline:
31
3
2022
entrez:
23
9
2021
Statut:
ppublish
Résumé
For almost a hundred years, the management of Type 1 diabetes has not advanced beyond insulin replacement. However, insulin does not provide satisfactory glycaemic control in the majority of individuals and there remains a major unmet need for novel treatments for Type 1 diabetes. Immunomodulation to preserve beta-cell function offers the prospect of making treatment with insulin easier and/or preventing the need for insulin, particularly when it comes to novel low-risk immunotherapies. Led by the concept that the best insulin-producing cell is a patient's own beta-cell, the Type 1 diabetes scientific community has a challenging task ahead-to fundamentally change the management of this devastating disease by using low-risk immunotherapy to preserve endogenous beta-cell function and make metabolic control substantially easier. In that way, insulin and/or beta-cell replacement (stem cell or transplantation) should in the future be considered rescue therapies reserved for delayed presentations.
Substances chimiques
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14696Informations de copyright
© 2021 Diabetes UK.
Références
Miller KM, Foster NC, Beck RW, et al. Current state of Type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38(6):971-978.
McKnight JA, Wild SH, Lamb MJ, et al. Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med. 2015;32(8):1036-1050.
Wasag DR, Gregory JW, Dayan C, Harvey JN, Brecon G. Excess all-cause mortality before age 30 in childhood onset Type 1 diabetes: data from the Brecon Group Cohort in Wales. Arch Dis Child. 2018;103(1):44-48.
Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic Type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974.
Greenbaum C, Lord S, VanBuecken D. Emerging concepts on disease-modifying therapies in Type 1 diabetes. Curr Diab Rep. 2017;17(11):119.
Thomas NJ, Lynam AL, Hill AV, et al. Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as Type 2 diabetes. Diabetologia. 2019;62(7):1167-1172.
Munoz C, Floreen A, Garey C, et al. Misdiagnosis and diabetic ketoacidosis at diagnosis of Type 1 diabetes: patient and caregiver perspectives. Clin Diabetes. 2019;37(3):276-281.
Hope SV, Wienand-Barnett S, Shepherd M, et al. Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis. Br J Gen Pract. 2016;66(646):e315-e322.
Foteinopoulou E, Clarke CAL, Pattenden RJ, et al. Impact of routine clinic measurement of serum C-peptide in people with a clinician-diagnosis of Type 1 diabetes. Diabet Med. 2020:e14449.
Peters JL, Anderson R, Shields B, et al. Strategies to identify individuals with monogenic diabetes: results of an economic evaluation. BMJ Open. 2020;10(3):e034716.
Jones AG, McDonald TJ, Shields BM, Hagopian W, Hattersley AT. Latent autoimmune diabetes of adults (LADA) is likely to represent a mixed population of autoimmune (Type 1) and nonautoimmune (Type 2) diabetes. Diabetes Care. 2021;44(6):1243-1251.
Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013;30(7):803-817.
Foteinopoulou E, Clarke CAL, Pattenden RJ, et al. Impact of routine clinic measurement of serum C-peptide in people with a clinician-diagnosis of Type 1 diabetes. Diabet Med. 2021;38(7):e14449.
Sharp SA, Rich SS, Wood AR, et al. Development and standardization of an improved Type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis. Diabetes Care. 2019;42(2):200-207.
Oram RA, Patel K, Hill A, et al. A Type 1 diabetes genetic risk score can aid discrimination between Type 1 and Type 2 diabetes in young adults. Diabetes Care. 2016;39(3):337-344.
Leete P, Willcox A, Krogvold L, et al. Differential insulitic profiles determine the extent of beta-cell destruction and the age at onset of Type 1 diabetes. Diabetes. 2016;65(5):1362-1369.
Long AE, Wilson IV, Becker DJ, et al. Characteristics of slow progression to diabetes in multiple islet autoantibody-positive individuals from five longitudinal cohorts: the SNAIL study. Diabetologia. 2018;61(6):1484-1490.
Pollanen PM, Lempainen J, Laine AP, et al. Characteristics of slow progression to Type 1 diabetes in children with increased HLA-conferred disease risk. J Clin Endocrinol Metab. 2019;104(11):5585-5594.
Greenbaum C, VanBuecken D, Lord S. Disease-modifying therapies in Type 1 diabetes: a look into the future of diabetes practice. Drugs. 2019;79(1):43-61.
Ferrat LA, Vehik K, Sharp SA, et al. A combined risk score enhances prediction of Type 1 diabetes among susceptible children. Nat Med. 2020;26(8):1247-1255.
Greenbaum CJ, Beam CA, Boulware D, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 diabetes TrialNet data. Diabetes. 2012;61(8):2066-2073.
Bogun MM, Bundy BN, Goland RS, Greenbaum CJ. C-peptide levels in subjects followed longitudinally before and after Type 1 diabetes diagnosis in TrialNet. Diabetes Care. 2020;43(8):1836-1842.
Dayan CM, Besser REJ, Oram RA, et al. Preventing Type 1 diabetes in childhood. Science. 2021;373(6554):506-510.
Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for Type 1 diabetes. N Engl J Med. 2019;381(7):603-613.
Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13(583).
Lachin JM, McGee P, Palmer JP, Group DER. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes. 2014;63(2):739-748.
Sorensen JS, Johannesen J, Pociot F, et al. Residual beta-cell function 3-6 years after onset of Type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care. 2013;36(11):3454-3459.
Jeyam A, Colhoun H, McGurnaghan S, et al. Clinical impact of residual C-Peptide secretion in Type 1 diabetes on glycemia and microvascular complications. Diabetes Care. 2021;44(2):390-398.
Helminen O, Aspholm S, Pokka T, et al. OGTT and random plasma glucose in the prediction of Type 1 diabetes and time to diagnosis. Diabetologia. 2015;58(8):1787-1796.
Vehik K, Cuthbertson D, Boulware D, et al. Performance of HbA1c as an early diagnostic indicator of Type 1 diabetes in children and youth. Diabetes Care. 2012;35(9):1821-1825.
Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59(11):2846-2853.
Lam CJ, Chatterjee A, Shen E, Cox AR, Kushner JA. Low-level insulin content within abundant non-beta islet endocrine cells in long-standing Type 1 diabetes. Diabetes. 2019;68(3):598-608.
Seiron P, Wiberg A, Kuric E, et al. Characterisation of the endocrine pancreas in Type 1 diabetes: islet size is maintained but islet number is markedly reduced. J Pathol Clin Res. 2019;5(4):248-255.
Bougneres PF, Landais P, Boisson C, et al. Limited duration of remission of insulin dependency in children with recent overt Type I diabetes treated with low-dose cyclosporin. Diabetes. 1990;39(10):1264-1272.
Jenner M, Bradish G, Stiller C, Atkison P. Cyclosporin A treatment of young children with newly-diagnosed type 1 (insulin-dependent) diabetes mellitus. London Diabetes Study Group. Diabetologia. 1992;35(9):884-888.
Ryden AK, Wesley JD, Coppieters KT, Von Herrath MG. Non-antigenic and antigenic interventions in Type 1 diabetes. Hum Vaccin Immunother. 2014;10(4):838-846.
Dayan CM, Korah M, Tatovic D, Bundy BN, Herold KC. Changing the landscape for Type 1 diabetes: the first step to prevention. Lancet. 2019;394(10205):1286-1296.
Haller MJ, Gitelman SE, Gottlieb PA, et al. Anti-thymocyte globulin/G-CSF treatment preserves beta cell function in patients with established Type 1 diabetes. J Clin Invest. 2015;125(1):448-455.
Haller MJ, Schatz DA, Skyler JS, et al. Low-dose anti-thymocyte globulin (ATG) preserves beta-cell function and improves HbA1c in new-onset Type 1 diabetes. Diabetes Care. 2018;41(9):1917-1925.
Cavallo MG, Pozzilli P, Bird C, et al. Cytokines in sera from insulin-dependent diabetic patients at diagnosis. Clin Exp Immunol. 1991;86(2):256-259.
Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset Type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care. 2009;32(7):1244-1249.
Quattrin T, Haller MJ, Steck AK, et al. Golimumab and beta-cell function in youth with new-onset Type 1 diabetes. N Engl J Med. 2020;383(21):2007-2017.
Roep BO, Wheeler DCS, Peakman M. Antigen-based immune modulation therapy for Type 1 diabetes: the era of precision medicine. Lancet Diabetes Endocrinol. 2019;7(1):65-74.
Alhadj Ali M, Liu YF, Arif S, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset Type 1 diabetes. Sci Transl Med. 2017;9(402).
von Herrath M, Bain SC, Bode B, et al. Anti-interleukin-21 antibody and liraglutide for the preservation of beta-cell function in adults with recent-onset Type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021;9(4):212-224.
Ovalle F, Grimes T, Xu G, et al. Verapamil and beta cell function in adults with recent-onset Type 1 diabetes. Nat Med. 2018;24(8):1108-1112.
Accili D. Whither Type 1 diabetes? N Engl J Med. 2020;383(21):2078-2079.
Persson S, Dahlquist G, Gerdtham UG, Steen Carlsson K. Impact of childhood-onset Type 1 diabetes on schooling: a population-based register study. Diabetologia. 2013;56(6):1254-1262.